Introduction: Although neuroendocrine neoplasms (NENs) have a good prognosis, distant metastasis remains a crucial prognostic factor. Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, indicating poor prognosis. We aimed to evaluate the clinical significance and role of survivin as a therapeutic target for NEN. Methods: We assessed the cytotoxicity of Survivin-2B (a splicing variant of survivin) 80-88 specific CTL clone with HLA-A24 restriction against NEN cell lines using intracellular staining for interferon-γ and assessed the frequency of Survivin-2B 80-88 CTL precursors in nine HLA-A24-positive patients with NEN using tetramer staining and compared it before and after resection. Finally, we evaluated the association between survivin expression and prognosis in 74 patients with pancreatic NEN using immunohistochemistry. Results: Survivin-2B 80-88 CTL clone showed high cytotoxicity against QGP-1 (HLA-A24 positive) cocultured with the Survivin-2B 80-88 peptide. Only three patients were positive for tetramer staining; two showed decreased Survivin-2B 80-88 CTL precursor following resection. The nuclear survivin-low group had a significantly better prognosis than the nuclear survivin-high group. Conclusion: Survivin in NEN is antigenic and may induce cellular immunity via the Survivin-2B CTL precursor. Survivin-targeting immunotherapy can be used to treat NEN with highly expressed Survivin-2B.

Survivin, a tumor-associated antigen, is overexpressed in several solid tumors, including neuroendocrine neoplasms (NENs), indicating poor prognosis. In this study, we evaluated the clinical significance and role of survivin as a therapeutic target for neuroendocrine neoplasms and the cytotoxicity of Survivin-2B 80-88 specific CTL clone with HLA-A24 restriction against NEN cell lines. Survivin-2B 80-88 CTL clone showed high cytotoxicity against QGP-1 (HLA-A24 positive) cocultured with the Survivin-2B 80-88 peptide. Next, we assessed the frequency of Survivin-2B 80-88 CTL precursors in nine HLA-A24-positive patients with NEN using tetramer staining and compared it before and after resection. Only 3 patients were positive for tetramer staining; two showed decreased Survivin-2B 80-88 CTL precursor following resection. Lastly, we evaluated the association between survivin expression and prognosis in 74 patients with pancreatic NEN using immunohistochemistry and showed that the nuclear survivin-low group had a significantly better prognosis than the nuclear survivin-high group.

1.
Dasari
A
,
Shen
C
,
Halperin
D
,
Zhao
B
,
Zhou
S
,
Xu
Y
, et al
.
Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States
.
JAMA Oncol
.
2017
;
3
(
10
):
1335
42
.
2.
Man
D
,
Wu
J
,
Shen
Z
,
Zhu
X
.
Prognosis of patients with neuroendocrine tumor: a SEER database analysis
.
Cancer Manag Res
.
2018
;
10
:
5629
38
.
3.
Frilling
A
,
Modlin
IM
,
Kidd
M
,
Russell
C
,
Breitenstein
S
,
Salem
R
, et al
.
Recommendations for management of patients with neuroendocrine liver metastases
.
Lancet Oncol
.
2014
;
15
(
1
):
e8
21
.
4.
Mandriani
B
,
Pellè
E
,
Mannavola
F
,
Palazzo
A
,
Marsano
RM
,
Ingravallo
G
, et al
.
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
.
J Immunother Cancer
.
2022
;
10
(
6
):
e004854
.
5.
Feng
Z
,
He
X
,
Zhang
X
,
Wu
Y
,
Xing
B
,
Knowles
A
, et al
.
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues
.
Nat Cancer
.
2022
;
3
(
5
):
581
94
.
6.
Rosenberg
SA
,
Yang
JC
,
Schwartzentruber
DJ
,
Hwu
P
,
Marincola
FM
,
Topalian
SL
, et al
.
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
.
Nat Med
.
1998
;
4
(
3
):
321
7
.
7.
Rosenberg
SA
.
A new era for cancer immunotherapy based on the genes that encode cancer antigens
.
Immunity
.
1999
;
10
(
3
):
281
7
.
8.
Ilyas
S
,
Yang
JC
.
Landscape of tumor antigens in T cell immunotherapy
.
J Immunol
.
2015
;
195
(
11
):
5117
22
.
9.
Ambrosini
G
,
Adida
C
,
Altieri
DC
.
A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
.
Nat Med
.
1997
;
3
(
8
):
917
21
.
10.
Li
F
,
Ambrosini
G
,
Chu
EY
,
Plescia
J
,
Tognin
S
,
Marchisio
PC
, et al
.
Control of apoptosis and mitotic spindle checkpoint by survivin
.
Nature
.
1998
;
396
(
6711
):
580
4
.
11.
Altieri
DC
.
The case for survivin as a regulator of microtubule dynamics and cell-death decisions
.
Curr Opin Cell Biol
.
2006
;
18
(
6
):
609
15
.
12.
Stauber
RH
,
Mann
W
,
Knauer
SK
.
Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential
.
Cancer Res
.
2007
;
67
(
13
):
5999
6002
.
13.
Hirohashi
Y
,
Torigoe
T
,
Maeda
A
,
Nabeta
Y
,
Kamiguchi
K
,
Sato
T
, et al
.
An HLA-A24-Restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin
.
Clin Cancer Res
.
2002
;
8
(
6
):
1731
9
.
14.
Idenoue
S
,
Hirohashi
Y
,
Torigoe
T
,
Sato
Y
,
Tamura
Y
,
Hariu
H
, et al
.
A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins
.
Clin Cancer Res
.
2005
;
11
(
4
):
1474
82
.
15.
Livak
KJ
,
Schmittgen
TD
.
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
.
Methods
.
2001
;
25
(
4
):
402
8
.
16.
Ueno
T
,
Tsuchikawa
T
,
Hatanaka
KC
,
Hatanaka
Y
,
Mitsuhashi
T
,
Nakanishi
Y
, et al
.
Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma
.
Oncotarget
.
2018
;
9
(
28
):
20034
47
.
17.
Tarhini
AA
,
Leng
S
,
Moschos
SJ
,
Yin
Y
,
Sander
C
,
Lin
Y
, et al
.
Safety and immunogenicity of vaccination with Mart 1 (26–35, 27L), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma
.
J Immunother
.
2012
;
35
(
4
):
359
66
.
18.
Maslak
PG
,
Dao
T
,
Bernal
Y
,
Chanel
SM
,
Zhang
R
,
Frattini
M
, et al
.
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia
.
Blood Adv
.
2018
;
2
(
3
):
224
34
.
19.
Pavlick
A
,
Blazquez
AB
,
Meseck
M
,
Lattanzi
M
,
Ott
PA
,
Marron
TU
, et al
.
Combined vaccination with NY-ESO-1 protein, poly-ICLC, and montanide improves humoral and cellular immune responses in patients with high-risk melanoma
.
Cancer Immunol Res
.
2020
;
8
(
1
):
70
80
.
20.
Grabowski
P
,
Griss
S
,
Arnold
CN
,
Hörsch
D
,
Göke
R
,
Arnold
R
, et al
.
Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease
.
Neuroendocrinology
.
2005
;
81
:
1
9
.
21.
Hanif
A
,
Lee
S
,
Gupta
M
,
Chander
A
,
Kannisto
ED
,
Punnanitinont
A
, et al
.
Exploring the role of survivin in neuroendocrine neoplasms
.
Oncotarget
.
2020
;
11
(
23
):
2246
58
.
22.
Tsuruma
T
,
Hata
F
,
Torigoe
T
,
Furuhata
T
,
Idenoue
S
,
Kurotaki
T
, et al
.
Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer
.
J Transl Med
.
2004
;
2
(
1
):
19
.
23.
Fenstermaker
RA
,
Ciesielski
MJ
,
Qiu
J
,
Yang
N
,
Frank
CL
,
Lee
KP
, et al
.
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
.
Cancer Immunol Immunother
.
2016
;
65
(
11
):
1339
52
.
24.
Shima
H
,
Tsurita
G
,
Wada
S
,
Hirohashi
Y
,
Yasui
H
,
Hayashi
H
, et al
.
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma
.
Cancer Sci
.
2019
;
110
(
8
):
2378
85
.
25.
Ahluwalia
MS
,
Reardon
DA
,
Abad
AP
,
Curry
WT
,
Wong
ET
,
Figel
SA
, et al
.
Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma
.
J Clin Oncol
.
2023
;
41
(
7
):
1453
65
.
26.
Gupta
M
,
Fenstermaker
RA
,
Qiu
J-X
,
Iyer
RV
.
A phase I study of safety and immunogenicity of survivin long peptide vaccine (SurVaxM) in patients (pts) with metastatic neuroendocrine tumors (NETs)
.
J Clin Orthod
.
2021
;
39
(
3_Suppl l
):
TPS375
.
27.
Fenstermaker
RA
,
Figel
SA
,
Qiu
J
,
Barone
TA
,
Dharma
SS
,
Winograd
EK
, et al
.
Survivin monoclonal antibodies detect survivin cell surface expression and inhibit tumor growth in vivo
.
Clin Cancer Res
.
2018
;
24
(
11
):
2642
52
.
28.
Lin
D
,
Shen
L
,
Luo
M
,
Zhang
K
,
Li
J
,
Yang
Q
, et al
.
Circulating tumor cells: biology and clinical significance
.
Signal Transduct Target Ther
.
2021
;
6
(
1
):
404
.
29.
Zhong
X
,
Zhang
H
,
Zhu
Y
,
Liang
Y
,
Yuan
Z
,
Li
J
, et al
.
Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy
.
Mol Cancer
.
2020
;
19
(
1
):
15
.
30.
Vay
C
,
Babaei
S
,
Safi
S-A
,
Dizdar
L
,
Rehders
A
,
Haeberle
L
, et al
.
Clinicopathological and prognostic value of survivin expression in surgically resected pancreatic ductal adenocarcinoma
.
Cancers
.
2022
:
14
.
31.
Oparina
N
,
Erlandsson
MC
,
Fäldt Beding
A
,
Parris
T
,
Helou
K
,
Karlsson
P
, et al
.
Prognostic significance of BIRC5/Survivin in breast cancer: results from three independent cohorts
.
Cancers
.
2021
;
13
(
9
):
2209
.
32.
Krieg
S
,
Roderburg
C
,
Fung
S
,
Luedde
T
,
Knoefel
WT
,
Krieg
A
.
Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis
.
J Cancer Res Clin Oncol
.
2022
;
148
(
9
):
2235
46
.
33.
Chu
X-Y
,
Chen
L-B
,
Wang
J-H
,
Su
Q-S
,
Yang
J-R
,
Lin
Y
, et al
.
Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer
.
J Surg Oncol
.
2012
;
105
(
6
):
520
8
.
34.
Yang
D
,
Schneider
S
,
Azuma
M
,
Iqbal
S
,
El-Khoueiry
A
,
Groshen
S
, et al
.
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer
.
Clin Colorectal Cancer
.
2006
;
6
(
4
):
305
11
.
35.
Yie
SM
,
Lou
B
,
Ye
SR
,
He
X
,
Cao
M
,
Xie
K
, et al
.
Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer
.
Lung Cancer
.
2009
;
63
(
2
):
284
90
.
36.
Galloway
NR
,
Ball
KF
,
Stiff
T
,
Wall
NR
.
Yin yang 1 (YY1): regulation of survivin and its role in invasion and metastasis
.
Crit Rev Oncog
.
2017
;
22
(
1–2
):
23
36
.
37.
Hanahan
D
,
Weinberg
RA
.
The hallmarks of cancer
.
Cell
.
2000
;
100
(
1
):
57
70
.
38.
Huber
MA
,
Kraut
N
,
Beug
H
.
Molecular requirements for epithelial-mesenchymal transition during tumor progression
.
Curr Opin Cell Biol
.
2005
;
17
(
5
):
548
58
.
39.
Yu
J
,
Wang
Z
,
Zhang
H
,
Wang
Y
,
Li
DQ
.
Survivin-positive circulating tumor cells as a marker for metastasis of hepatocellular carcinoma
.
World J Gastroenterol
.
2021
;
27
(
43
):
7546
62
.
40.
Liu
F
,
Sun
Y
,
Liu
B
,
Lu
J
,
Li
H
,
Zhu
H
, et al
.
Insulin-like growth factor-1 induces epithelial-mesenchymal transition in hepatocellular carcinoma by activating survivin
.
Oncol Rep
.
2018
;
40
(
2
):
952
8
.
41.
Li
F
,
Ackermann
EJ
,
Bennett
CF
,
Rothermel
AL
,
Plescia
J
,
Tognin
S
, et al
.
Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
.
Nat Cell Biol
.
1999
;
1
(
8
):
461
6
.
42.
Yoshikawa
K
,
Shimada
M
,
Higashijima
J
,
Nakao
T
,
Nishi
M
,
Takasu
C
, et al
.
Ki-67 and survivin as predictive factors for rectal cancer treated with preoperative chemoradiotherapy
.
Anticancer Res
.
2018
;
38
(
3
):
1735
9
.
43.
Khan
S
,
Bennit
HF
,
Turay
D
,
Perez
M
,
Mirshahidi
S
,
Yuan
Y
, et al
.
Early diagnostic value of survivin and its alternative splice variants in breast cancer
.
BMC Cancer
.
2014
;
14
:
176
.
44.
Dong
H
,
Qian
D
,
Wang
Y
,
Meng
L
,
Chen
D
,
Ji
X
, et al
.
Survivin expression and serum levels in pancreatic cancer
.
World J Surg Oncol
.
2015
;
13
:
189
.
45.
Ren
YQ
,
Zhang
HY
,
Su
T
,
Wang
XH
,
Zhang
L
.
Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma
.
Eur Rev Med Pharmacol Sci
.
2014
;
18
(
20
):
3063
8
.
46.
Jakubowska
K
,
Pryczynicz
A
,
Dymicka-Piekarska
V
,
Famulski
W
,
Guzińska-Ustymowicz
K
.
Immunohistochemical expression and serum level of survivin protein in colorectal cancer patients
.
Oncol Lett
.
2016
;
12
(
5
):
3591
7
.
You do not currently have access to this content.